• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国识别家族性高胆固醇血症患者面临的挑战与机遇:来自国家家族性高胆固醇血症患者登记与筛查数据库的证据

Challenges and opportunities for identifying people with familial hypercholesterolemia in the UK: Evidence from the National FH PASS database.

作者信息

Cox Edward, Faria Rita, Saramago Pedro, Haralambos Kate, Watson Melanie, Humphries Steve E, Qureshi Nadeem, Woods Beth

机构信息

Centre for Health Economics, University of York, UK, YO10 5DD; Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK, NG7 2RD.

Centre for Health Economics, University of York, UK, YO10 5DD.

出版信息

J Clin Lipidol. 2024 Nov-Dec;18(6):e1046-e1054. doi: 10.1016/j.jacl.2024.08.007. Epub 2024 Sep 4.

DOI:10.1016/j.jacl.2024.08.007
PMID:39317596
Abstract

BACKGROUND

Familial hypercholesterolemia (FH) is a monogenic disorder that causes high levels of low-density lipoprotein (LDL) cholesterol. Cascade testing, where relatives of known individuals with FH ('index') are genetically tested, is effective and cost-effective, but implementation in the UK varies.

OBJECTIVE

This study aims to provide evidence on current UK FH cascade yields and to identify common obstacles cascade services face and individual- and service-level predictors of success.

METHODS

Electronic health records from 875 index families and 5,958 linked relatives in the UK's Welsh and Wessex FH services (2019) were used to explore causes for non-testing and to estimate testing rates, detection yields, and how relative characteristics and contact methods relate to the probability of relatives being tested (using logistic regression).

RESULTS

In Wales (Wessex), families included 7.35 (7.01) members on average, with 2.41 (1.66) relatives tested and 1.35 (0.96) diagnosed with FH per index. Cascade testing is limited by individualized circumstances (too young, not at-risk, etc.) and FH services' reach, with approximately one in four relatives out-of-area. In Wales, first-degree relatives (odds ratio (OR): 1.55 [95% confidence interval (CI): 1.28, 1.88]) and directly contacted relatives (OR: 2.11 [CI: 1.66, 2.69]) were more likely to be tested. In Wales and Wessex, women were more likely to be tested than men (ORs: 1.53 [CI: 1.28, 1.85] and 1.74 [CI: 1.32, 2.27]).

CONCLUSION

In Wales and Wessex less than a third of relatives of an index are tested for FH. Improvements are likely possible by integrating geographically dispersed families into cascade testing, services directly contacting relatives where possible, and finding new ways to encourage participation, particularly amongst men.

摘要

背景

家族性高胆固醇血症(FH)是一种导致低密度脂蛋白(LDL)胆固醇水平升高的单基因疾病。级联检测是对已知FH患者(“索引病例”)的亲属进行基因检测,这种方法有效且具有成本效益,但在英国的实施情况各不相同。

目的

本研究旨在提供有关英国当前FH级联检测产出的证据,并确定级联检测服务面临的常见障碍以及成功的个体和服务层面预测因素。

方法

使用来自英国威尔士和韦塞克斯FH服务机构(2019年)的875个索引病例家庭和5958名相关亲属的电子健康记录,以探究未进行检测的原因,并估计检测率、检出率,以及亲属特征和联系方法与亲属接受检测概率之间的关系(使用逻辑回归)。

结果

在威尔士(韦塞克斯),每个索引病例家庭平均有7.35(7.01)名成员,有2.41(1.66)名亲属接受检测,其中1.35(0.96)名被诊断为FH。级联检测受到个体情况(年龄太小、无风险等)和FH服务覆盖范围的限制,约四分之一的亲属不在服务区域内。在威尔士,一级亲属(优势比(OR):1.55 [95%置信区间(CI):1.28,1.88])和直接联系的亲属(OR:2.11 [CI:1.66,2.69])接受检测的可能性更大。在威尔士和韦塞克斯,女性接受检测的可能性高于男性(OR分别为:1.53 [CI:1.28,1.85]和1.74 [CI:1.32,2.27])。

结论

在威尔士和韦塞克斯,不到三分之一的索引病例亲属接受了FH检测。通过将地理上分散的家庭纳入级联检测、服务机构尽可能直接联系亲属以及寻找鼓励参与的新方法,特别是在男性中,可能会有所改善。

相似文献

1
Challenges and opportunities for identifying people with familial hypercholesterolemia in the UK: Evidence from the National FH PASS database.英国识别家族性高胆固醇血症患者面临的挑战与机遇:来自国家家族性高胆固醇血症患者登记与筛查数据库的证据
J Clin Lipidol. 2024 Nov-Dec;18(6):e1046-e1054. doi: 10.1016/j.jacl.2024.08.007. Epub 2024 Sep 4.
2
Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis.替代级联检测方案用于识别和管理家族性高胆固醇血症患者:系统评价、定性研究和成本效益分析。
Health Technol Assess. 2023 Oct;27(16):1-140. doi: 10.3310/CTMD0148.
3
Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK.基于英国家族性高胆固醇血症服务机构的数据,对家族性高胆固醇血症的级联检测的成本效益进行评估。
Eur Heart J. 2017 Jun 14;38(23):1832-1839. doi: 10.1093/eurheartj/ehx111.
4
The evaluation of cascade testing for familial hypercholesterolemia.家族性高胆固醇血症的级联检测评估。
Am J Med Genet A. 2012 Jan;158A(1):78-84. doi: 10.1002/ajmg.a.34368. Epub 2011 Dec 2.
5
Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.家族性高胆固醇血症的基因检测:卫生技术评估。
Ont Health Technol Assess Ser. 2022 Aug 23;22(3):1-155. eCollection 2022.
6
Effectiveness of cascade testing strategies in relatives for familial hypercholesterolemia: A systematic review and meta-analysis.家族性高胆固醇血症患者亲属中级联检测策略的有效性:系统评价和荟萃分析。
Atherosclerosis. 2021 Dec;338:7-14. doi: 10.1016/j.atherosclerosis.2021.09.014. Epub 2021 Oct 2.
7
Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.基于不同诊断和识别策略的家族性高胆固醇血症级联筛查的概率成本效益分析。
Heart. 2011 Jul;97(14):1175-81. doi: 10.1136/hrt.2010.213975.
8
Reverse cascade screening for familial hypercholesterolemia in high-risk Chinese families.中国高危家庭中家族性高胆固醇血症的反向级联筛查
Clin Cardiol. 2017 Nov;40(11):1169-1173. doi: 10.1002/clc.22809. Epub 2017 Nov 23.
9
Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience.利用集中协调的临床服务对家族性高胆固醇血症进行基因级联筛查的有效性:澳大利亚的经验。
Atherosclerosis. 2015 Mar;239(1):93-100. doi: 10.1016/j.atherosclerosis.2014.12.036. Epub 2014 Dec 23.
10
Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.高胆固醇血症筛查与家族性高胆固醇血症病例发现:系统评价与成本效益分析
Health Technol Assess. 2000;4(29):1-123.